Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3371 |
Name | chondrosarcoma |
Definition | A bone sarcoma that has_material_basis_in cells derived from transformed cells that produce cartilage. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3370 |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma chondrosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
IDH1 mutant | Dasatinib | chondrosarcoma | resistant | detail... |
IDH1 R132C | Ivosidenib | chondrosarcoma | predicted - sensitive | detail... |
IDH1 R132G | Ivosidenib | chondrosarcoma | predicted - sensitive | detail... |
IDH1 R132L | Ivosidenib | chondrosarcoma | predicted - sensitive | detail... |
IDH1 R132S | Ivosidenib | chondrosarcoma | predicted - sensitive | detail... |
IDH1 act mut | Ivosidenib | chondrosarcoma | sensitive | detail... |
MLH1 negative | Pembrolizumab | chondrosarcoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | chondrosarcoma | sensitive | detail... |
IDH1 R132S | Olaparib | chondrosarcoma | predicted - sensitive | detail... |
IDH1 R132C | Olaparib | chondrosarcoma | predicted - sensitive | detail... |
IDH2 R172S | Ceralasertib + Olaparib | chondrosarcoma | sensitive | detail... |
IDH1 act mut | Olutasidenib | chondrosarcoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01446809 | Phase I | Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib | Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02389244 | Phase II | Regorafenib | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) | Active, not recruiting | FRA | 0 |
NCT03190174 | Phase Ib/II | Nab-rapamycin + Nivolumab | Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma | Completed | USA | 0 |
NCT03277924 | Phase Ib/II | Nivolumab + Sunitinib | Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) | Completed | ITA | GBR | ESP | 0 |
NCT03282344 | Phase II | Nivolumab + NKTR-214 | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT04040205 | Phase II | Abemaciclib | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Recruiting | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04278781 | Phase II | Ivosidenib | AG-120 in People With IDH1 Mutant Chondrosarcoma | Active, not recruiting | USA | 0 |
NCT04340843 | Phase II | Belinostat + Guadecitabine | Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | Active, not recruiting | USA | 0 |
NCT04458922 | Phase II | Atezolizumab | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | Active, not recruiting | USA | CAN | 0 |
NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | AUS | 5 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04950075 | Phase II | INBRX-109 | Study of INBRX-109 in Conventional Chondrosarcoma | Recruiting | USA | NLD | ITA | IRL | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05131386 | Phase II | Dexamethasone + Trabectedin | Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) | Recruiting | ESP | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT06127407 | Phase III | Ivosidenib | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER) | Recruiting | USA | CAN | BRA | AUS | 1 |
NCT06176989 | Phase II | Enasidenib | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | Recruiting | USA | 0 |